King & Wood Mallesons has advised Trea Asset Management on the structuring of its new investment vehicle, Trea Healthcare Ventures Fund.

The fund is the result of the collaboration between the Spanish manager Trea AM and Discovery Ventures, specialized in life sciences and experienced in investing in successful companies such as Quethera, Orchard Therapeutics or Gensight.

The vehicle falls under Article 9 of the European SFDR regulation for its positive social impact and is intended to invest in biotechnology companies, medical devices or technologies applied to health that develop new techniques such as gene therapy, advanced cell therapy, nano-biotechnology, bionics, tissue engineering and artificial intelligence.

The team of KWM lawyers who have participated in this project has been led by the partner and director of the funds department Isabel Rodríguez, together with the associates Enrique Torné and Lara Taylor.

Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

Eleventh acquisition under Meridia's JV ...

by Meridia Capital Partners

This acquisition signifies Meridia's entry into one of the most esteem...

Photos Stream